Global 7 diagnostics9/25/2023 ![]() “Broad, fast, and accurate COVID-19 diagnosis outside the hospital setting remains one of the main challenges in this relentless pandemic, especially now that we are clearly facing yet another wave of infections. As part of the Institute’s collective response to the COVID-19 pandemic, the team leveraged their eRapid technology to build an effective SARS-CoV-2 detection system to meet the long term challenge of providing point-of-care diagnostics for use in physician’s offices, pharmacies, or at home, which might be used to identify whether a patient is actively infected or if he or she has been infected or vaccinated in the past and has developed an active immune response. Simultaneously analyzing the presence of multiple different biomarkers related to the patient’s infection state can provide enhanced diagnostic sensitivity and specificity, and better inform physicians. Credit: Wyss Institute at Harvard Universityĭeveloped in a cross-disciplinary team effort led by the Wyss’ Founding Director Donald Ingber, M.D., Ph.D., and Wyss Senior Staff Scientist Pawan Jolly, Ph.D., the eRapid technology is a low-cost, affinity-based electrochemical sensing platform that can multiplex simultaneous detection and quantification of a broad range of biomarkers, including proteins, antibodies, RNA, and small molecules with high sensitivity and selectivity in small quantities of complex biological fluids, such as blood or saliva. ![]() eRapid is an electrochemical sensing platform that uses a novel antifouling coating to enable low-cost, multiplexed detection of a wide range of biomolecules for diagnostics and other applications. The licensing agreement was coordinated by Harvard’s Office of Technology Development (OTD) in accordance with the University’s commitment to the COVID-19 Technology Access Framework. The Australian consortium will integrate the biomarker detection technology with its transistor technology to enable specific and sensitive SARS-Co-V-2 testing in addressing the global diagnostic gap in the rampant coronavirus pandemic. (BOSTON) - Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic applications. The low-cost electrochemical technology for multiplexed biomarker detection could facilitate global serological testing for SARS-CoV-2 infections, and help trace immunity in individuals over time ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |